| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥79.8B | ¥65.1B | +22.4% |
| Operating Income | ¥1.9B | ¥3.4B | -42.4% |
| Ordinary Income | ¥1.7B | ¥2.4B | -29.7% |
| Net Income | ¥0.1B | ¥1.6B | -94.1% |
| ROE | 0.3% | 4.3% | - |
FY2025 Q3 results: Revenue 79.8B yen (YoY +22.4%), Operating Income 1.9B yen (YoY -42.4%), Ordinary Income 1.7B yen (YoY -29.7%), Net Income 0.1B yen (YoY -94.1%). The company achieved strong top-line growth primarily driven by the Medical segment expansion through ONE MEDICAL acquisition and segment reorganization, contributing an incremental 20.9B yen in revenue. However, profitability deteriorated significantly across all profit levels. Operating margin compressed to 2.4% from 5.2% in the prior year period, reflecting substantial increases in SG&A expenses that outpaced revenue growth. The gross profit margin remained stable at 57.0%, but SG&A expenses reached 43.5B yen (54.5% of revenue), creating minimal operating leverage. Net income declined 94.1% to 0.1B yen due to combined pressures from elevated tax burden (effective tax rate approximately 86.6%), interest expenses of 0.4B yen, and extraordinary losses of 1.1B yen. This represents a revenue up/profit down pattern with severe bottom-line compression.
Revenue growth of +22.4% to 79.8B yen was primarily attributable to the newly established Medical segment reporting 20.9B yen in revenue following the acquisition of ONE MEDICAL in November 2024 and segment reorganization that separated medical services from the Platform segment. Excluding the Medical segment, the three legacy segments contributed 56.9B yen. The Broadband segment generated 27.1B yen (declining slightly from 28.0B yen prior year), Platform segment contributed 25.0B yen (down from 26.0B yen), and SaaS and DX segment delivered 6.8B yen (roughly flat at 6.7B yen). The revenue composition shift toward Medical reflects strategic emphasis under the mid-term plan EXCITE300 targeting Medical-centric growth. On the profit side, operating income declined 42.4% to 1.9B yen despite the revenue expansion. Segment operating profit analysis reveals the Medical segment recorded a loss of 1.6B yen (margin -7.5%), while SaaS and DX also posted losses of 0.8B yen (margin -11.2%). Only Platform (3.3B yen profit, margin 13.3%) and Broadband (4.0B yen profit, margin 14.9%) generated positive operating income. Corporate overhead costs increased to 3.1B yen from 4.6B yen in adjustments, indicating substantial unallocated general and administrative expenses. The gap between operating income (1.9B yen) and ordinary income (1.7B yen) narrowed compared to prior year, with net non-operating expenses of 0.2B yen primarily consisting of interest expenses (0.4B yen) partially offset by dividend income (0.2B yen) and interest income (0.1B yen). The substantial divergence between ordinary income (1.7B yen) and net income (0.1B yen) reflects extraordinary losses of 1.1B yen and an abnormally high income tax expense of 0.6B yen against profit before tax of only 0.7B yen, resulting in an effective tax rate exceeding 85%. This represents a revenue up/profit down scenario driven by operational deleverage from loss-making new segments, elevated fixed costs, and non-recurring factors heavily compressing net profitability.
The Medical segment, newly established this period following the ONE MEDICAL acquisition and reorganization, generated revenue of 20.9B yen but recorded an operating loss of 1.6B yen with a negative margin of 7.5%, representing the largest segment by revenue but a significant drag on consolidated profitability. The Broadband segment, the core legacy business, contributed 27.1B yen in revenue with operating income of 4.0B yen and the highest margin of 14.9%, maintaining stable profitability despite modest revenue decline from 28.0B yen prior year. The Platform segment generated 25.0B yen in revenue with operating income of 3.3B yen and margin of 13.3%, declining from 26.0B yen revenue and 4.1B yen operating income in the prior period. The SaaS and DX segment reported 6.8B yen revenue with an operating loss of 0.8B yen (margin -11.2%), consistent with prior year losses. Broadband remains the core profit-generating business by absolute operating income contribution, though Medical now represents the largest revenue segment at 26.2% of total consolidated revenue. The material margin differential between profitable legacy segments (Broadband 14.9%, Platform 13.3%) and loss-making growth segments (Medical -7.5%, SaaS and DX -11.2%) highlights the profitability challenge as the company shifts toward Medical-centric growth under its mid-term plan.
[Profitability] ROE 0.3% deteriorated sharply from 4.4% prior year, reflecting severe net income compression; operating margin 2.4% declined 2.8pt from 5.2% YoY as SG&A expenses at 54.5% of revenue exceeded the prior year ratio; net profit margin 0.1% collapsed from 2.5% YoY due to elevated tax burden and extraordinary losses; gross profit margin maintained at 57.0% indicates stable pricing but insufficient operating leverage. [Cash Quality] Cash and deposits 21.0B yen cover short-term debt of 7.5B yen at 2.8x, providing adequate liquidity cushion; operating cash generation quality is undermined by extended receivables collection at DSO of 111 days compared to 103 days prior year. [Investment Efficiency] Total asset turnover 0.74 indicates sluggish asset utilization relative to revenue generation; goodwill of 31.4B yen represents 89.8% of total equity at 35.0B yen, creating substantial impairment risk; intangible assets total 39.1B yen or 36.1% of total assets, reflecting M&A-driven asset composition. [Financial Health] Equity ratio 32.3% declined from 35.1% YoY, indicating deteriorating financial stability; current ratio 151.8% provides reasonable short-term solvency though below the prior year 176.5%; debt-to-equity ratio 2.09 exceeds conservative thresholds at 2.0x, with interest-bearing debt of 46.5B yen comprising long-term loans of 39.0B yen and short-term borrowings of 7.5B yen; interest coverage measured as EBIT/interest expense stands at 4.8x (1.9B yen operating income / 0.4B yen interest), indicating manageable but compressed debt service capacity.
Cash and deposits increased 0.9B yen YoY to 21.0B yen, representing 19.4% of total assets and providing a liquidity buffer of 2.8x short-term debt coverage. The modest cash accumulation occurred despite significant net income decline, suggesting operating activities generated sufficient cash to offset earnings deterioration. Working capital dynamics show trade receivables increased 4.4B yen to 24.3B yen, with DSO extending to 111 days from 103 days prior year, indicating slower collection efficiency that absorbs cash. Trade payables increased 1.4B yen to 8.6B yen, reflecting improved supplier credit utilization that partially offsets receivables pressure. Inventories surged 1.1B yen to 1.3B yen, a 491% increase suggesting either business model shift toward inventory-holding operations or inventory buildup related to the Medical segment expansion. On the investment side, property, plant and equipment increased dramatically from 0.1B yen to 3.6B yen, while intangible assets grew from 36.5B yen to 39.1B yen, indicating substantial capital deployment. Goodwill rose from 30.0B yen to 31.4B yen, consistent with the ONE MEDICAL acquisition. Financing activities show long-term loans increased 1.9B yen to 39.0B yen while short-term borrowings rose 2.5B yen to 7.5B yen, indicating debt-funded growth investments. The combination of extended receivables collection, inventory buildup, and increased borrowing suggests the company is in an investment phase prioritizing growth over immediate cash efficiency, with adequate liquidity maintained but working capital management requiring monitoring.
Ordinary income of 1.7B yen versus operating income of 1.9B yen shows net non-operating expenses of approximately 0.2B yen, representing 0.3% of revenue. This primarily comprises interest expenses of 0.4B yen partially offset by dividend income of 0.2B yen and interest income of 0.1B yen from financial activities. The financial expense structure reflects the company's leveraged capital structure with interest-bearing debt of 46.5B yen generating recurring interest burden. Non-operating income contribution is relatively modest as a percentage of revenue, consisting mainly of returns on investment securities holdings of 10.7B yen. Earnings quality is significantly impaired by extraordinary items and tax distortions. Profit before tax of 0.7B yen faced income tax expense of 0.6B yen, yielding an effective tax rate of approximately 86.6% that is abnormally elevated compared to statutory rates, suggesting deferred tax adjustments or non-deductible expenses that distort reported profitability. Extraordinary losses totaled 1.1B yen against extraordinary income of 0.1B yen, creating a net extraordinary burden of 1.0B yen equivalent to 1.3% of revenue. While specific details are not disclosed, such items represent non-recurring factors that mask core operating performance. The combination of high tax burden, extraordinary losses, and the fact that net income of 0.1B yen represents only 5.9% of operating income indicates severely compromised earnings quality. Cash flow assessment is constrained by limited CF statement data, though the extended DSO of 111 days and inventory buildup suggest operating cash generation may lag reported earnings, warranting caution on earnings sustainability.
Full-year guidance targets revenue of 110.0B yen (YoY +21.0%), operating income of 6.1B yen (YoY +30.9%), and ordinary income of 5.6B yen (YoY +57.8%). Q3 cumulative progress against these targets stands at 72.5% for revenue, 31.7% for operating income, and 29.8% for ordinary income. Revenue progress is appropriately ahead of the 75% standard for Q3, consistent with the strong top-line momentum. However, operating income and ordinary income progress rates of approximately 30% significantly lag the expected 75% benchmark, indicating substantial shortfall in profitability relative to plan. Achieving full-year guidance requires Q4 to generate approximately 30.2B yen revenue (realistic given Q3 run-rate), but critically 4.2B yen operating income and 3.9B yen ordinary income, representing dramatic improvement from the 1.9B yen and 1.7B yen respectively in Q3 cumulative. This implies Q4 standalone would need to deliver operating margin near 14% compared to the 2.4% achieved in the first nine months, presenting execution risk. No forecast revisions were announced this quarter, suggesting management maintains confidence in H2 recovery driven by Medical segment maturation and cost management. The guidance assumes net income of 3.2B yen for the full year, implying EPS of 66.17 yen, which requires Q4 net income of approximately 3.1B yen to overcome the cumulative 0.1B yen through Q3. Forecast notes indicate estimates are based on currently available information with inherent risks and uncertainties, warranting investor caution given the significant profit recovery required in Q4. The guidance credibility hinges on realization of Medical segment turnaround and elimination of extraordinary losses that depressed Q1-Q3 results.
Annual dividend forecast of 31.50 yen per share comprises 30.00 yen year-end dividend, representing modest increase from the prior year comparable level. Against Q3 cumulative basic EPS of 2.70 yen, the implied payout ratio reaches 1,167% (31.50/2.70), which is arithmetically unsustainable and reflects the denominator distortion from depressed earnings. Using the full-year forecast EPS of 66.17 yen, the normalized payout ratio calculates to 47.6% (31.50/66.17), which falls within conventional ranges assuming earnings guidance is achieved. However, given the substantial gap between year-to-date profitability and full-year targets, dividend sustainability warrants monitoring. The company's cash position of 21.0B yen and positive operating cash generation provide buffer to support dividend payments even if net income underperforms, though continued dividend at current levels absent earnings recovery would erode capital over time. No share buyback programs are disclosed in the current period, resulting in total shareholder return being limited to dividends. Total return ratio mirrors the payout ratio at 47.6% based on forecast earnings, indicating moderate capital return relative to profitability targets. The combination of high forecast payout ratio, lack of supplementary buybacks, and execution risk on earnings guidance suggests shareholder return policy assumes profit recovery materialization, with dividend stability dependent on achieving full-year net income targets of 3.2B yen substantially above current run-rate.
Medical segment profitability risk: The newly expanded Medical segment generated 20.9B yen revenue but recorded operating loss of 1.6B yen (margin -7.5%) in Q3, representing the largest segment by revenue but a 1.6B yen drag on consolidated operating income. The mid-term plan EXCITE300 centers on Medical-centric growth targeting FY2028 revenue of 15.5B yen with EBITDA of 2.3B yen, requiring substantial margin improvement from current loss-making status. Failure to achieve Medical segment turnaround would undermine both growth and profitability targets, with integration risks from the ONE MEDICAL acquisition including customer retention, operational synergies, and regulatory compliance in online medical services.
Financial leverage and interest burden risk: Debt-to-equity ratio of 2.09x exceeds conservative thresholds with interest-bearing debt of 46.5B yen against equity of 35.0B yen. Interest expenses of 0.4B yen in Q3 cumulative represent 21.1% of operating income, creating significant financial leverage that constrains net profitability. Long-term loans of 39.0B yen comprise the bulk of debt, while short-term borrowings increased 50% YoY to 7.5B yen, elevating refinancing risk. Rising interest rate environments would further compress margins, and debt covenants if breached could trigger acceleration. The company's interest coverage of 4.8x (operating income/interest expense) provides modest cushion but limited room for earnings deterioration without debt service stress.
Goodwill impairment and asset quality risk: Goodwill of 31.4B yen represents 89.8% of total equity and 29.0% of total assets, with intangible assets totaling 39.1B yen or 36.1% of assets, reflecting M&A-driven growth including the ONE MEDICAL acquisition. The Medical segment's negative 7.5% operating margin and SaaS and DX segment's negative 11.2% margin raise questions about cash-generating ability of acquired businesses. Any material deterioration in segment performance or adverse changes in business plans could trigger impairment testing failures, resulting in significant non-cash charges that would erode equity. The high goodwill-to-equity ratio of 89.8% means even a 10% impairment would reduce equity by approximately 9%, materially weakening the balance sheet. No impairment losses are reported this period, but sustained segment losses increase future impairment probability.
[Industry Position] (Reference - Proprietary Analysis) The company operates in the IT and Telecommunications sector comprising 104 companies. Profitability metrics show ROE of 0.3% substantially below the industry median of 8.3% (IQR: 3.6%-13.1%), ranking in the bottom decile and indicating severely impaired capital efficiency relative to peers. Operating margin of 2.4% significantly trails the industry median of 8.2% (IQR: 3.6%-18.0%), placing the company in the lower quartile and reflecting operational leverage challenges from loss-making segments. Net profit margin of 0.1% dramatically underperforms the industry median of 6.0% (IQR: 2.2%-12.7%), consistent with extraordinary losses and elevated tax burden compressing bottom-line results. Financial health metrics show equity ratio of 32.3% below the industry median of 59.2% (IQR: 42.5%-72.7%), indicating higher financial leverage than typical sector participants. Current ratio of 1.52x falls below the industry median of 2.15x (IQR: 1.57x-3.62x), suggesting tighter liquidity positioning. The debt-to-equity ratio of 2.09x derived from financial leverage of 3.09x significantly exceeds the industry median financial leverage of 1.66x (IQR: 1.36-2.32), confirming above-average leverage utilization. Efficiency metrics show asset turnover of 0.74x aligns closely with the industry median of 0.67x (IQR: 0.49-0.93), indicating comparable asset utilization despite profitability challenges. Receivables turnover of 111 DSO exceeds the industry median of 61 days (IQR: 46-83 days), highlighting collection inefficiency requiring management attention. Growth metrics show revenue growth of 22.4% YoY substantially outperforms the industry median of 10.4% (IQR: -1.2%-19.6%), placing the company in the top quartile for top-line expansion driven by Medical segment addition. However, the Rule of 40 metric combining growth and profitability would approximate 24.8% (22.4% revenue growth + 2.4% operating margin), below the industry median of 20.0% (IQR: 5%-34%) when considering margin weakness offsets growth strength. Overall, the company demonstrates superior revenue growth positioning but materially underperforms on profitability, capital efficiency, and financial health relative to industry benchmarks, reflecting the investment phase and integration challenges of M&A-driven expansion.
※ Industry: IT and Telecommunications (104 companies), Comparison: FY2025 Q3, Source: Proprietary analysis
Strong revenue growth trajectory driven by strategic Medical segment expansion positions the company in the top quartile of industry growth at 22.4% YoY versus 10.4% median, validating the EXCITE300 mid-term plan's focus on Medical-centric growth through the ONE MEDICAL acquisition. However, this growth comes at substantial profitability cost with operating margin of 2.4% significantly below the 8.2% industry median and ROE of 0.3% ranking in the bottom decile against 8.3% median, indicating the company is sacrificing near-term profitability for market position building in loss-making Medical (margin -7.5%) and SaaS and DX (margin -11.2%) segments while legacy Broadband and Platform segments maintain healthy 14.9% and 13.3% margins respectively.
Financial leverage at 2.09x debt-to-equity substantially exceeds the industry norm with financial leverage of 3.09x versus 1.66x median, creating interest burden of 0.4B yen that consumes 21% of operating income and constrains flexibility. The elevated leverage combined with goodwill of 31.4B yen representing 89.8% of equity creates dual risks of debt service pressure and potential impairment charges if acquired business performance deteriorates, particularly given the Medical segment's current loss-making status. Cash position of 21.0B yen providing 2.8x short-term debt coverage offers near-term liquidity buffer, though extended receivables at 111 DSO versus 61 days industry median indicates working capital management requires improvement.
The full-year guidance implies dramatic Q4 profit recovery with operating income needing to reach approximately 4.2B yen in Q4 standalone versus 1.9B yen cumulative through Q3, representing execution risk that warrants monitoring of quarterly progress. Dividend policy maintaining 31.50 yen per share implies 47.6% payout ratio against forecast EPS of 66.17 yen, which appears sustainable if earnings targets are achieved but faces sustainability questions if profitability underperforms given the 1,167% payout ratio against depressed year-to-date EPS of 2.70 yen. The investment case centers on whether the company can successfully transition loss-making growth segments to profitability while maintaining legacy business margins, with the mid-term plan targeting FY2028 operating margin improvement to 10.3% (16B yen operating income on 155B yen revenue) requiring substantial operational leverage realization over the next three years.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.